Foundayo's Slow Start in Weight-Loss Drug Race

Eli Lillys new weight-loss pill, Foundayo, saw a modest start with 3,707 prescriptions in its second week, falling short of analysts expectations. Novo Nordisks Wegovy, launched earlier, had 18,410 prescriptions in its second week. Lilly, with a later approval and rollout, is hoping for a stronger showing as investors watch closely to see if Foundayo can gain momentum in the competitive oral obesity drug market. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fd40a86ab649ed27